Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?

Bimekizumab has shown comparable efficacy in PsA patients who are TNFi naive and TNFi inadequate responders. Therefore, I would choose bimekizumab in bDMARD-IR patients. My second answer might surprise you - I would choose bimekizumab in a PsA patient with recurrent uveitis.

Bimekizumab might be especially beneficial for patients with a heavy burden of arthritis and psoriasis.

First line therapy for any new PsA/PsO drug is always difficult in the US but we try.